Evidence map›Paper›PMID 37792268›Full record

ArticleBiological trace element research2024

Exploring the Therapeutic Potential of Fe

Zahra Mahdavi Niyaki, Ali Salehzadeh, Maryam Peymani, Mohammad Zaefizadeh

Abstract read
PubMed Publisher
In one paragraph

Article in Biological trace element research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Zahra Mahdavi NiyakiDepartment of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran.
Ali SalehzadehDepartment of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran. salehzadeh@iaurasht.ac.ir.
Maryam PeymaniDepartment of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. m.peymani@iaushk.ac.ir.
Mohammad ZaefizadehDepartment of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran.
Islamic Azad University Rasht Branch · IRIslamic Azad University Ardabil · IRIslamic Azad University of Shahrekord · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer, the leading cause of death worldwide, has witnessed significant advancements in treatment through targeted therapies. Among the proto-oncogenes prevalent in human cancers, KRAS stands out, and recent research has focused on long noncoding RNAs (lncRNAs) as regulators of miRNAs targeting the KRAS oncogene. This study specifically explores lncRNAs involved in the KRAS pathway in colorectal cancer (CRC). To investigate this, researchers employed iron oxide nanoparticles coated with glucose and conjugated with Oleuropein (Fe

Indexed as

Colorectal NeoplasmsNanoparticlesProto-Oncogene Proteins p21(ras)RNA, Long NoncodingAntineoplastic AgentsApoptosisCell ProliferationDrug Screening Assays, AntitumorFerrosoferric OxideHumansIridoid GlucosidesAntineoplastic AgentsFerrosoferric OxideIridoid GlucosidesKRAS protein, humanoleuropeinProto-Oncogene Proteins p21(ras)RNA, Long NoncodingColorectal cancerKRASLncRNAOleuropein

Identifiers

PMID37792268
OpenAlexW4387326402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.